1345982-69-5 Usage
Description
GSK 2330672 is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT) with high potency in inhibiting human, mouse, and rat ASBT. It has been shown to stimulate fecal bile acid secretion, reduce hemoglobin A1c (HbA1c) and plasma glucose levels, and increase total GLP-1 and plasma insulin in Zucker diabetic fatty (ZDF) rats.
Uses
Used in Pharmaceutical Industry:
GSK 2330672 is used as a therapeutic agent for the treatment of diabetes and related metabolic disorders. It functions by inhibiting the apical sodium-dependent bile acid transporter (ASBT), which leads to increased fecal bile acid secretion, reduced hemoglobin A1c (HbA1c) and plasma glucose levels, and increased total GLP-1 and plasma insulin in diabetic rats. This makes it a promising candidate for the development of new treatments for diabetes and other metabolic conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1345982-69-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,4,5,9,8 and 2 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1345982-69:
(9*1)+(8*3)+(7*4)+(6*5)+(5*9)+(4*8)+(3*2)+(2*6)+(1*9)=195
195 % 10 = 5
So 1345982-69-5 is a valid CAS Registry Number.
1345982-69-5Relevant articles and documents
SYNTHESIS OF BENZOTHIAZEPINES
-
, (2016/04/19)
Methods for preparing the following compound are disclosed.
CHEMICAL COMPOUNDS
-
, (2011/11/13)
Compounds of Formula (I) and methods for treating metabolic disorders are disclosed.
